Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.60 |
| ▸ | ECE1 | P42892 | 1/20 | 0.60 |
| ▸ | CASP3 | P42574 | 2/20 | 0.59 |
| ▸ | CTSL | P07711 | 3/20 | 0.57 |
| ▸ | CTSS | P25774 | 3/20 | 0.57 |
| ▸ | CTSB | P07858 | 2/20 | 0.57 |
| ▸ | CTSK | P43235 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
| ▸ | CTSD | P07339 | 1/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
| ▸ | CASP7 | P55210 | 1/20 | 0.56 |
| ▸ | CASP9 | P55211 | 1/20 | 0.56 |
| ▸ | CASP6 | P55212 | 1/20 | 0.56 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.56 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9829372 | 1.00 | MME (0.60) | MMEECE1CASP3CTSLCTSS | |
| SCHEMBL19776145 | 1.00 | MME (0.60) | MMEECE1CASP3CTSLCTSS | |
| SCHEMBL10452681 | 0.91 | MME (0.56) | MMEECE1CTSLCTSSCTSB | |
| SCHEMBL5689424 | 0.91 | CASP3 (0.58) | CASP3CTSLCTSSCTSBCTSK | |
| SCHEMBL13637586 | 0.91 | CASP3 (0.58) | CASP3CTSLCTSSCTSBCTSK | |
| SCHEMBL7378851 | 0.90 | ECE1 (0.64) | MMEECE1CASP3CTSLCTSS | |
| SCHEMBL6272667 | 0.90 | ECE1 (0.64) | MMEECE1CASP3CTSLCTSS | |
| SCHEMBL15947169 | 0.90 | CASP3 (0.57) | ECE1CASP3CTSLCTSSCTSB | |
| SCHEMBL7327620 | 0.89 | CAPN1 (0.64) | MMEECE1CASP3CTSLCTSS | |
| SCHEMBL19557810 | 0.89 | CASP3 (0.61) | CASP3CTSLCTSSCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351780-B2 | Peptide acetals for stabilising enzymes | BASF SE (DE) | 2025-07-08 | — | — | US | claimed |
| US-20220267699-A1 | PEPTIDE ACETALS FOR STABILISING ENZYMES | BASF SE (DE) | 2022-08-25 | — | — | US | claimed |
| EP-3994148-A1 | PEPTIDE ACETALS FOR STABILISING ENZYMES | BASF SE (DE) | 2022-05-11 | — | — | EP | claimed |
| EP-4725560-A2 | ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2026-04-15 | — | — | EP | disclosed |
| US-12590273-B2 | Stabilized glycoside hydrolase variants | NOVOZYMES A/S (DK) | 2026-03-31 | — | — | US | disclosed |
| EP-4637748-A2 | PNU ANTHRACYCLINE-DERIVED LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12391934-B2 | Stabilized cellulase variants | NOVOZYMES A/S (DK) | 2025-08-19 | — | — | US | disclosed |
| EP-3953463-B1 | STABILIZED GLYCOSIDE HYDROLASE VARIANTS | NOVOZYMES AS (DK) | 2025-08-06 | — | — | EP | disclosed |
| US-20250170252-A1 | QUINONE PROTECTED FORMS AND CONJUGATES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2025-05-29 | — | — | US | disclosed |
| EP-4532480-A1 | QUINONE PROTECTED FORMS AND CONJUGATES | Cambridge Enterprise Limited (GB) | 2025-04-09 | — | — | EP | disclosed |
| US-20250099600-A1 | Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-03-27 | — | — | US | disclosed |
| US-5847135-A | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-12-08 | — | — | US | disclosed |
| WO-1998053091-A1 | SCREENING ASSAYS FOR AGENTS THAT ALTER INHIBITOR OF APOPTOSIS (IAP) PROTEIN REGULATION OF CASPASE ACTIVITY | THE BURNHAM INSTITUTE (US) | 1998-11-26 | — | — | WO | disclosed |
| US-5716929-A | THERAPY FOR INFLAMMATION, AUTOIMMUNE DISEASES | VERTEX PHARMACEUTICALS, INC. (US) | 1998-02-10 | — | — | US | disclosed |
| US-5656627-A | USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE AND NEURODEGENERATIVE DISEASES | VERTEX PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| EP-0784628-A1 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1997-07-23 | — | — | EP | disclosed |
| WO-1995035308-A1 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-12-28 | — | — | WO | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267699-A1 | PEPTIDE ACETALS FOR STABILISING ENZYMES | IDE, PEPD, PREP | MME 123/4885ECE1 910/4885CASP3 2668/4885 |
| US-12351780-B2 | Peptide acetals for stabilising enzymes | IDE, PEPD, PREP | MME 123/4885ECE1 910/4885CASP3 2668/4885 |
| US-12590273-B2 | Stabilized glycoside hydrolase variants | IDUA, IDE, TREH | MME 542/4885ECE1 1568/4885CASP3 4067/4885 |
| US-20250099600-A1 | Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates | KIF18B, KIF18A, KIF5B | MME 3629/4885ECE1 3854/4885CASP3 3888/4885 |
| US-20250170252-A1 | QUINONE PROTECTED FORMS AND CONJUGATES | NQO1, SQOR, GSTP1 | MME 433/4885ECE1 2073/4885CASP3 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.